The high incidence of left atrial appendage thrombosis in patients on maintenance haemodialysis

Nephrology Dialysis Transplantation

Volumn 18, Issue 11, 2003, Pages 2339-2347

  Nishimura, Masato ^a   Hashimoto, Tetsuya ^a   Kobayashi, Hiroyuki ^a   Fukuda, Toyofumi ^a   Okino, Koji ^a   Yamamoto, Noriyuki ^a   Iwamoto, Noriyuki ^b   Nakamura, Naoto ^b   Yoshikawa, Toshikazu ^b   Ono, Toshihiko ^a  

^a KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Antiplatelet therapy; Diabetes mellitus; Haematocrit; Haemodialysis; Left atrial appendage; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; RECOMBINANT ERYTHROPOIETIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM APPENDAGE; HEART ATRIUM THROMBOSIS; HEART LEFT ATRIUM; HEMATOCRIT; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; SMOKING HABIT; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

AGED; ATRIAL APPENDAGE; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HEART DISEASES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; THROMBOSIS;

EID: 10744230439     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg399     Document Type: Article

References (21)

1. Cerebral Embolism Task Force. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol 1989; 46: 727-743
2. McNamara RL, Lima JA, Whelton PK, Powe NR. Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: a cost effectiveness analysis. Ann Intern Med 1997; 127: 775-787
3. Leung DY, Davidson PM, Cranney GB, Walsh WF. Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. Am J Cardiol 1997; 79: 626-629
4. Atrial Fibrillation Investigators. Atrial Fibrillation, Aspirin, Anticoagulation Study; European Atrial Fibrillation Study; Stroke Prevention in Atrial Fibrillation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Study; Veterans Affairs Prevention in Atrial Fibrillation Study. Echocardiographic predictors of strokes in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158: 1316-1320
5. Manning WJ, Weintraub RM, Waksmonski CA et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med 1995; 123: 817-822
6. Iseki K, Fukiyama K, The Okinawa Dialysis Study (OKIDS) Group. Clinical demographics and long-term prognosis after stroke in patients on chronic haemodialysis. Nephrol Dial Transplant 2000; 15: 1808-1813
7. Devereux RB, Koren MJ, deSimone G, Okin PM, Kligfield P. Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur Heart J 1993; 14 [Suppl D]: 8-15
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360
9. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581
10. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994; 45: 1477-1483
11. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate induced platelet alpha-granule release. Blood 1993; 82: 505-512
12. Weksler BB, Pett SB, Alonso D et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308: 800-805
13. Weber E, Haas TA, Muller TH, Eisert WG, Hirsh J. Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenicity following injury: influence of salicylate and dipyridamole treatment. Thromb Res 1990; 57: 383-392
14. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104-109
15. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213-2221
16. De Marchi S, Cecchin E, Falleti E et al. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 1997; 8: 1147-1156
17. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin. N Engl J Med 1998; 339: 584-590
18. Wakeen M, Zimmerman SW. Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 1998; 32: 488-493
19. Arnaout MA, Hakim RM, Todd RF, 3rd, Dana N, Colten HR. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 1985; 312: 457-462
20. Shaldon S, Deschodt G, Branger B et al. Haemodialysis hypotension: the interleukin hypothesis restated. Proc Eur Dial Transplant Assoc 1985; 22: 229-243
21. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300: 729-735